We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Is Omalizumab Treatment Used During the COVID-19 Pandemic Effective on the Frequency and Severity of COVID-19?
- Authors
KARA, Rabia ÖZTAŞ; DİKİCİER, Bahar SEVİMLİ; KARA, Ahmet; YAĞMUR, Ahmet Can; YALDIZ, Mahizer
- Abstract
Objective: The effects of drugs used in chronic spontaneous urticaria (CSU) and similar chronic dermatological diseases in COVID-19 continue to be the subject of many studies. The present study aimed to reveal the frequency and severity of COVID-19 infection in CSU patients treated with omalizumab and antihistamines. Materials and Methods: CSU patients who were followed up and treated with omalizumab or antihistamines were evaluated retrospectively for clinical conditions with CSU and COVID-19 during the pandemic and compared with the control group regarding the incidence and severity of COVID-19 infection. In addition, urticaria disease severity was also compared with pre-pandemic scores for the CSU group. Results: Real-time reverse transcription-polymerase chain reaction test positivity rate for SARS-CoV-2 was detected in 17.4%, 30.1%, and 34.8% of the patients in omalizumab, antihistamine, and control groups, respectively (p= 0.001). The disease activity scores were increased in both antihistamine and omalizumab treated compared to the precovid state CSU patients, while the increase was minor in patients using omalizumab. Conclusion: The fact that COVID-19 infection was seen less frequent and urticaria activity scores were lower during the infection in the omalizumab group suggests that omalizumab treatment is safe and convenient to use during COVID-19 infection.
- Subjects
COVID-19 pandemic; OMALIZUMAB; SEVERITY of illness index; ANTIHISTAMINES; CONTROL groups; DISEASE incidence
- Publication
Online Turkish Journal of Health Sciences (OTJHS) / Online Türk Sağlık Bilimleri Dergisi, 2023, Vol 8, Issue 3, p369
- ISSN
2459-1467
- Publication type
Article
- DOI
10.26453/otjhs.1282836